Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213413 | 1.00 | ADRA1A (0.43) | ADRA1AADRA1DADRA2ACHRM4CHRM1 | |
| SCHEMBL23209953 | 0.83 | ADRA1A (0.43) | ADRA1AADRA1DADRA2ACHRM4CHRM1 | |
| SCHEMBL23209955 | 0.83 | ADRA1A (0.43) | ADRA1AADRA1DADRA2ACHRM4CHRM1 | |
| SCHEMBL23213043 | 0.82 | CHRM4 (0.41) | ADRA1AADRA1DADRA2ACHRM4CHRM1 | |
| SCHEMBL23213036 | 0.82 | CHRM4 (0.41) | ADRA1AADRA1DADRA2ACHRM4CHRM1 | |
| SCHEMBL23229953 | 0.81 | CHRM4 (0.41) | CHRM4CHRM1CHRM2 | |
| SCHEMBL23213740 | 0.80 | CHRM4 (0.43) | ADRA1AADRA1DCHRM4CHRM1CHRM2 | |
| SCHEMBL23213744 | 0.80 | CHRM4 (0.43) | ADRA1AADRA1DCHRM4CHRM1CHRM2 | |
| SCHEMBL23213474 | 0.77 | CHRM4 (0.48) | CHRM4CHRM1CHRM2 | |
| SCHEMBL23213478 | 0.77 | CHRM4 (0.48) | CHRM4CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390705-A | 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-114555606-B | 5-Oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2022-11-01 | — | — | US | disclosed |
| EP-4041737-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555606-A | 5-oxa-2-azaspiro [3.4] octane derivatives as M4 agonists | 诺华股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021070091-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | ADRA1A 13/4885ADRA1D 19/4885ADRA2A 12/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | ADRA1A 13/4885ADRA1D 19/4885ADRA2A 12/4885 |
| US-20210130365-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | ADRA1A 13/4885ADRA1D 19/4885ADRA2A 12/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | ADRA1A 13/4885ADRA1D 20/4885ADRA2A 12/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | ADRA1A 13/4885ADRA1D 19/4885ADRA2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.